Welcome to the trials list!

Some tips to help get started:

  • Click on any trial title to view details, including trial sites, eligibility criteria, and our research about study drugs
  • If the list is long, use the search box and filters on the left to narrow down trials
  • Bookmark trials of interest by clicking the bookmark icon to the right of the trial title
Sign up to save your data! Arrow
Processing... Processing...

Clinical Trials for Other Solid Tumor

Search

Close
[Clear]

Filters

Location:
[Clear]
[Clear]

There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.

397 trials meet filter criteria.

Sort by:

Investigational drug late phase More information Active drug More information High burden on patient More information
Sponsor: BioNTech SE (industry) Phase: 2 Start date: March 3, 2025

HealthScout AI summary: This trial targets patients with Stage IV NSCLC who have progressed after first-line chemoimmunotherapy and explores the combination of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, with docetaxel.

ClinicalTrials.gov ID: NCT06841055

Investigational drug late phase More information Active drug More information High burden on patient More information
Sponsor: AbbVie (industry) Phase: 2 Start date: Jan. 20, 2025

HealthScout AI summary: The trial targets adult patients with c-Met overexpressing, EGFR wild-type, non-squamous, locally advanced or metastatic NSCLC who have progressed after prior treatment, evaluating two regimens of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met by delivering the cytotoxic agent MMAE to tumor cells.

ClinicalTrials.gov ID: NCT06568939

Investigational drug late phase More information Active drug More information High burden on patient More information
Sponsor: Prelude Therapeutics (industry) Phase: 2 Start date: Nov. 12, 2024

HealthScout AI summary: This trial involves patients with advanced, recurrent, or metastatic solid tumors, such as esophageal cancer or NSCLC, that harbor a SMARCA4 mutation and have progressed on or are ineligible for standard therapies; it evaluates the investigational SMARCA2 degrader PRT3789 in combination with the PD-1 inhibitor pembrolizumab.

ClinicalTrials.gov ID: NCT06682806

Investigational drug late phase More information Active drug More information High burden on patient More information
Sponsor: Merck Sharp & Dohme LLC (industry) Phase: 2 Start date: Dec. 13, 2024

HealthScout AI summary: The trial enrolls treatment-naïve patients with Stage IV squamous or non-squamous NSCLC and evaluates the combination of the HER3-DXd patritumab deruxtecan, an antibody-drug conjugate targeting HER3, with pembrolizumab, with or without platinum-based chemotherapy. Participants must have an ECOG performance status of 0 or 1 and meet specific health criteria for inclusion.

ClinicalTrials.gov ID: NCT06731907

Active drug More information Moderate burden on patient More information
Sponsor: Immuneering Corporation (industry) Phase: 1/2 Start date: Oct. 31, 2022

HealthScout AI summary: This trial targets adult patients with advanced or metastatic solid tumors harboring RAS mutations, testing the safety and efficacy of IMM-1-104, a novel dual MEK1/2 inhibitor, as monotherapy or combined with mGnP or mFFX. Participants have conditions like PDAC, RAS-mutant melanoma, and NSCLC.

ClinicalTrials.gov ID: NCT05585320

Active drug More information Moderate burden on patient More information
Sponsor: Erasca, Inc. (industry) Phase: 1 Start date: Aug. 17, 2023

HealthScout AI summary: This trial assesses the safety and efficacy of naporafenib, a pan-RAF kinase inhibitor, combined with trametinib, a MEK inhibitor, in patients aged 12 and older with previously treated, RAS Q61X-mutated locally advanced unresectable or metastatic solid tumors lacking standard treatment options. Patients with neurologically unstable primary CNS tumors or CNS metastases are excluded.

ClinicalTrials.gov ID: NCT05907304

Active drug More information Moderate burden on patient More information
Sponsor: Daiichi Sankyo (industry) Phase: 1/2 Start date: Oct. 30, 2024

HealthScout AI summary: This trial compares the combination of pembrolizumab and valemetostat tosylate, a dual EZH1/2 inhibitor, with pembrolizumab alone in patients with advanced or metastatic non-small cell lung cancer expressing PD-L1 ≥50% and lacking actionable genomic alterations. It includes patients who have not received prior systemic therapy and have a performance status of 0 or 1.

ClinicalTrials.gov ID: NCT06644768

Investigational drug late phase More information Active drug More information High burden on patient More information Started >3 years ago More information
Sponsor: Yale University (other) Phase: 2 Start date: Feb. 4, 2021

HealthScout AI summary: The trial evaluates NC318, a Siglec-15-targeting monoclonal antibody, alone or with pembrolizumab in patients with advanced non-small cell lung cancer who have progressed following PD-1 inhibitor therapy or are PD-1 inhibitor naïve. It includes multiple treatment arms based on prior treatments and tumor PD-L1 expression levels.

ClinicalTrials.gov ID: NCT04699123

Active drug More information Moderate burden on patient More information
Sponsor: Revolution Medicines, Inc. (industry) Phase: 1/2 Start date: Jan. 18, 2024

HealthScout AI summary: The trial involves adult patients with locally advanced or metastatic RAS-mutated NSCLC who have received prior standard therapy and are treated with investigational oral RAS(ON) inhibitors RMC-6236 and RMC-6291, targeting various RAS mutations, including KRAS G12C, in combination with standard treatments like pembrolizumab and chemotherapy agents.

ClinicalTrials.gov ID: NCT06162221

Active drug More information Moderate burden on patient More information
Sponsor: Kiromic BioPharma Inc. (industry) Phase: 1 Start date: Nov. 7, 2023

HealthScout AI summary: This trial involves patients with stage 4 metastatic non-small cell lung cancer who have not responded to at least two standard treatments, assessing the safety and efficacy of intravenous allogeneic gamma delta T-cell product, KB-GDT-01, combined with low-dose radiotherapy, aimed at enhancing the immune system's ability to recognize and destroy tumor cells.

ClinicalTrials.gov ID: NCT06069570

First Previous Page 6 of 40 Next Last
Please help us improve by giving us feedback or feature requests. Email [email protected]
Copy email address
Email copied to clipboard